Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CHRNG | P07510 | 1/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRND | Q07001 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920507 | 0.88 | KMT2A (0.58) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL18920477 | 0.87 | LMNA (0.56) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL18920448 | 0.86 | MEN1 (0.55) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL8690417 | 0.81 | KMT2A (0.62) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL15063135 | 0.80 | LMNA (0.68) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL7657250 | 0.79 | LMNA (0.94) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL15063303 | 0.78 | ALDH1A1 (0.71) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL2789416 | 0.78 | LMNA (0.97) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL1819794 | 0.78 | LMNA (0.97) | ALDH1A1MEN1LMNAKMT2AOPRM1 | |
| SCHEMBL14428555 | 0.77 | L3MBTL1 (0.53) | ALDH1A1MEN1LMNAKMT2AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349965-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093301-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLRX3 | ALDH1A1 290/4885MEN1 1815/4885LMNA 4602/4885 |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLRX3 | ALDH1A1 290/4885MEN1 1815/4885LMNA 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.